BeyondSpring Presents Plans for 442-Patient Phase 3 Plinabulin Trial in Post-ICI Lung Cancer

Bitget2026/10/26 03:14

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BeyondSpring plans to start its 442-patient DUBLIN-4 confirmatory Phase 3 trial of plinabulin in 2026-2027.
The trial compares plinabulin with docetaxel against docetaxel alone in post-immunotherapy, driver-negative, non-squamous lung cancer.
Overall survival is the primary endpoint; interim analysis is expected in 2028 following 221 progression-free survival events.
Prior DUBLIN-3 data showed median survival of 11.37 months versus 8.81 months in non-squamous patients, with a 0.72 hazard ratio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on October 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BeyondSpring Presents Plans for 442-Patient Phase 3 Plinabulin Trial in Post-ICI Lung Cancer

You may also like

Crypto prices